new_0222_0393|OMGA|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0393|OMGA|1|Omega Therapeutics Inc Total Current Assets (Quarterly) (USD)|Omega Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Omega Therapeutics Inc Inventories (Quarterly) (USD)|Omega Therapeutics Inc Net PP&E (Quarterly) (USD)|Omega Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Omega Therapeutics Inc Total Liabilities (Quarterly) (USD)|Omega Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Omega Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Omega Therapeutics Inc Total Deposits (Quarterly) (USD)|Omega Therapeutics Inc Book Value (Quarterly) (USD)|Omega Therapeutics Inc Retained Earnings (Quarterly) (USD)|Omega Therapeutics Inc Treasury Stock (Quarterly) (USD)|Omega Therapeutics Inc EV to Revenues|Omega Therapeutics Inc EV to Earnings|Omega Therapeutics Inc EV to Free Cash Flow|Omega Therapeutics Inc EV to Assets (Quarterly)|Omega Therapeutics Inc PS Ratio|Omega Therapeutics Inc PE Ratio|Omega Therapeutics Inc Price to Book Value|Omega Therapeutics Inc PEG Ratio|Omega Therapeutics Inc Debt to Equity Ratio|Omega Therapeutics Inc Dividend Yield|Omega Therapeutics Inc Shareholder Yield (TTM)|Omega Therapeutics Inc Percent of Shares Outstanding Short|Omega Therapeutics Inc Total Receivables (Quarterly) (USD)|Omega Therapeutics Inc Total Payables (Quarterly) (USD)|Omega Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Omega Therapeutics Inc Return on Invested Capital|Omega Therapeutics Inc Quality Ratio Score|Omega Therapeutics Inc Momentum Score|Omega Therapeutics Inc Beta (1Y)|Omega Therapeutics Inc Sustainable Growth Rate (TTM)|Omega Therapeutics Inc Institutional Investor Ownership Percentage|Omega Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Omega Therapeutics Inc Total Employees (Annual)|Omega Therapeutics Inc EPS Diluted (Quarterly) (USD)|Omega Therapeutics Inc SG&A Expense (Quarterly) (USD)|Omega Therapeutics Inc Shares Outstanding|Omega Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Omega Therapeutics Inc Ordinary Shares Number (Quarterly)|Omega Therapeutics Inc Payout Ratio|Omega Therapeutics Inc Quick Ratio (Quarterly)|Omega Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Omega Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Omega Therapeutics Inc Effective Tax Rate (TTM)|Omega Therapeutics Inc Return on Equity|Omega Therapeutics Inc Net Income (TTM) (USD)|Omega Therapeutics Inc Revenue (TTM) (USD)|Omega Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Omega Therapeutics Inc Revenue (Quarterly) (USD)|Omega Therapeutics Inc Gross Profit (Quarterly) (USD)|Omega Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Omega Therapeutics Inc Net Income (Quarterly) (USD)|Omega Therapeutics Inc Net Interest Income (Quarterly) (USD)|Omega Therapeutics Inc Price (USD)|Omega Therapeutics Inc Total Return Price (USD)|Omega Therapeutics Inc Enterprise Value (USD)|Omega Therapeutics Inc 30-Day Average Daily Volume|Omega Therapeutics Inc 1 Year Price Returns (Daily)|Omega Therapeutics Inc Short Interest|Omega Therapeutics Inc PE Ratio (Forward)|Omega Therapeutics Inc PE Ratio (Forward 1y)|Omega Therapeutics Inc PS Ratio (Forward)|Omega Therapeutics Inc PS Ratio (Forward 1y)|Omega Therapeutics Inc Quarterly EPS Estimates (USD)|Omega Therapeutics Inc Quarterly Revenue Estimates (USD)|Omega Therapeutics Inc Quarterly EPS Surprise|Omega Therapeutics Inc Quarterly Revenue Surprise|Omega Therapeutics Inc Quarterly Actual EPS (USD)|Omega Therapeutics Inc Quarterly Actual Revenue (USD)|Omega Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Omega Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Omega Therapeutics Inc Price Target (USD)|Omega Therapeutics Inc Consensus Recommendation|Omega Therapeutics Inc Price Target Num Estimates|Omega Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Omega Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Omega Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Omega Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Omega Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Omega Therapeutics Inc Land and Improvements (Quarterly) (USD)|Omega Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Omega Therapeutics Inc Other Properties (Quarterly) (USD)|Omega Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0393|OMGA|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0393|OMGA|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0393|OMGA|5|91|91||91||91|91|91||91|91||||1.43971631206||||1.4387755102|||1.43971631206||15.4166666667|91|91|91||||||30.6666666667|91.3333333333||91.3333333333|91.3333333333|25.25||91|||91.3333333333|91.25|||91|||||91.3333333333|91.3333333333|91.3333333333|1.43971631206|1.43971631206|1.43971631206|1.4375||15.4166666667|||||91.5|91.5|92||92|92|35.25|47|28.2|17.625|28.2|20.1428571429|20.1428571429|91.3333333333|91.3333333333|91.3333333333|||91|91||
new_0222_0393|OMGA|6|3|3||3||3|3|3||3|3||||141||||98|||141||12|3|3|3||||||6|6||6|6|4||3|||6|4|||3|||||6|6|6|141|141|141|112||12|||||6|6|1||1|1|4|3|5|8|5|7|7|6|6|6|||3|3||
new_0222_0393|OMGA|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0393|OMGA|202003||||||||||||||||||||||||||||||||||31.1264||-0.1741|1.365||||||-0.1742|||||||||-5.418|-5.418|-0.194||||||||||||||||||||||||3.521|0.216|0.194||||||
new_0222_0393|OMGA|202006||||||||||||||||||||||||||||||||||31.1264||-0.2031|1.01||||||-0.2032|||||||||-6.323|-6.323|-0.194||||||||||||||||||||||||4.895|0.225|0.194||||||
new_0222_0393|OMGA|202009||||||||||||||||||||||||||||||||||31.1264||-0.2648|2.047||||||-0.2648|||||||||-8.241|-8.241|-0.196||||||||||||||||||||||||5.505|0.274|0.196||||||
new_0222_0393|OMGA|202012|24.003|22.951||3.482||92.711|7.699|85.012||-64.628|-66.225||||||||||||||0.193|1.063|0.005|||||||31.1264||-0.3041|1.814|||46.7258|||-0.3041||||-29.447|||||-9.465|-9.465|-0.193||||||||||||||||||||||||7.142|0.431|0.193|||3.444|1.114||
new_0222_0393|OMGA|202103|139.784|137.767||3.644||221.949|9.726|212.223||-77.877|-79.713||||||||||||||0.248|3.353|0.005|||||||31.1264||-0.43|2.745|||46.7258|||-0.4194||||-37.517|||||-13.488|-13.488|-0.212||||||||||||||||||||||||9.748|0.302|0.212|||3.492|1.114||
new_0222_0393|OMGA|202106|125.297|122.411||4.1||222.53|11.8|210.73||-92.484|-95.123||||-14.9599|||||||||0.6054|0.04|1.169|0.005||||||13.2173|46.7258|65|-0.3298|3.637|46.7258||46.7258|||-0.3296||||-46.604|||||-15.41|-15.41|-0.19|16|16|637.0078|||282898|||||-3.23||-4.0248||-3.36||||29.5|1.75|4|-2.3833|-3.2267|11.184|0.337|0.19|||4.225|1.176|18.18|
new_0222_0393|OMGA|202109|238.759|234.275||3.785||22.932|14.309|8.623||220.339|-113.651||||-13.1061||||4.0866|||||0.7611|0.367|0.911|0.048||||||95.4643|32.3035||-0.57|4.459|47.7686||47.7686|||-0.54|-131.238|||-56.891|||||-18.528|-18.528|-0.339|18.85|18.85|678.1481|114308.1667||363560|||||-0.4433||-28.5724||-0.57||||29.5|1.75|4|-2.5367|-3.1633|12.289|0.364|0.339|||4.532|1.176|29.38|18.09
new_0222_0393|OMGA|202112|||||||||||||||-6.1651||||2.4566|||||1.3076|||||||||95.4786||||||||||||||||||||||11.33|11.33|318.9996|98837.6333||624712|||||-0.5133||||||||29.5|1.75|4|-2.8567|-3.5||||||||11.36|11.5
new_0222_0393|OMGA|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.59|||||||||||||||||||||
new_0222_0393|OMGA|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.665|||||||||||||||||||||
new_0222_0393|OMGA|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.75|||||||||||||||||||||
new_0222_0393|OMGA|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.76|||||||||||||||||||||